Package Leaflet: Information for the User
Nexium 40 mg Powder for Solution for Injection and Infusion
esomeprazole
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the Pack
Nexium contains a medicine called esomeprazole which belongs to a group of medicines called “proton pump inhibitors”. These work by reducing the amount of acid that the stomach produces.
Nexium is used to treat the following conditions when treatment by mouth is not possible:
Adults
Children and adolescents from 1 to 18 years of age
You will not be given Nexium
If you are in any of these situations, you will not be given Nexium. If you are not sure, consult your doctor, pharmacist, or nurse before you are given this medicine.
Warnings and precautions
Tell your doctor or nurse before you are given Nexium if:
Nexium may mask the symptoms of other diseases. Therefore, if you notice any of the following before you are given Nexium or after you have been given it, contact your doctor immediately:
Taking a proton pump inhibitor like Nexium, especially over a period of more than one year, may slightly increase the risk of fracture of the hip, wrist, or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).
Skin rashes and skin symptoms
If you get a skin rash, especially in areas exposed to the sun, tell your doctor as soon as possible, as you may need to stop treatment with Nexium. Remember to mention any other symptoms that you may notice, such as joint pain.
Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported in association with Nexium treatment. Stop taking Nexium and seek immediate medical attention if you notice any of the symptoms related to these severe skin reactions described in section 4.
Using Nexium with other medicines
Tell your doctor or nurse if you are taking, have recently taken, or might take any other medicines. This includes medicines that you buy without a prescription. This is because Nexium may affect how some medicines work and some medicines may affect how Nexium works.
You will not be given Nexium if you are taking a medicine that contains nelfinavir (used to treat HIV infection).
Tell your doctor if you are using any of the following medicines:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine. Your doctor will decide whether you can be given Nexium during this time.
It is not known if Nexium passes into breast milk. Therefore, you should not take Nexium during breastfeeding.
Driving and using machines
Nexium is unlikely to affect your ability to drive or use tools or machines. However, side effects such as dizziness or blurred vision (see section 4) may occur. Do not drive or use machines if you experience any of these effects.
Nexium can be given to children and adolescents from 1 to 18 years of age and to adults, including the elderly.
Use in adults
Use in children and adolescents
If you are given too much Nexium
If you think you have been given too much Nexium, tell your doctor immediately.
In case of overdose or accidental ingestion, contact the Toxicology Information Service. Telephone 91 5620420, stating the medicine and the amount given.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any of the following serious side effects, stop taking Nexium and contact a doctor immediately:
These effects are rare and may affect up to 1 in 1,000 people.
These effects are rare and may affect up to 1 in 1,000 people.
Other side effects include:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (frequency cannot be estimated from the available data)
In very rare cases, Nexium may affect the white blood cells, leading to immune deficiency. If you have an infection with symptoms such as fever with a severe deterioration of your general condition or fever with symptoms of a local infection such as pain in the neck, throat, mouth, or difficulty urinating, you should contact your doctor as soon as possible to rule out a decrease in the number of white blood cells (agranulocytosis) by a blood test. It is important that you inform your doctor about your medication.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Store the vial in the outer packaging to protect it from light. However, the vials can be stored outside the packaging exposed to indoor light for up to 24 hours.
Nexium Composition
Product Appearance and Container Contents
Nexium is a porous cake or white to off-white powder. Before administration, it is reconstituted into a solution.
Packages: 1 vial, 10 vials. Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Grünenthal Pharma, S.A.
Doctor Zamenhof, 36 – 28027 Madrid, Spain
Manufacturer
AstraZeneca AB, 152 57Södertälje, Sweden
Grünenthal GmbH, Zieglerstrasse 6- D- 52078 Aachen, Germany
This medication is authorized in the Member States of the European Economic Area under the following names:
Member State | Medicinal Product Name |
Austria, Denmark, Finland, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden | Nexium |
Belgium, Luxembourg | Nexiam |
France | Inexium |
Portugal | Nexium I.V. |
Date of the Last Revision of this Leaflet: May 2025
Other Sources of Information
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
This information is intended only for healthcare professionals:
Nexium 40 mg contains 40 mg of esomeprazole, as sodium salt. Each vial also contains disodium edetate and sodium hydroxide (<1 mmol of sodium).
The vials are for single use. If the complete contents of the reconstituted vial are not used for a single dose, the unused solution must be discarded.
For more information on dosage recommendations and storage conditions, see sections 3 and 5, respectively.
Preparation and Administration of the Reconstituted Solution:
To reconstitute the solution, remove the colored plastic cap from the top of the Nexium vial and puncture the stopper in the center of the marked circle, keeping the needle in a vertical position, in order to correctly pierce the stopper.
The reconstituted solution for injection or infusion must be transparent and colorless to slightly yellow. It must be visually inspected for particles and discoloration before administration and only the clear solution should be used.
The shelf life after reconstitution has been demonstrated in terms of physical and chemical stability for 12 hours at 30°C. However, from a microbiological point of view, the product must be used immediately.
Nexium Injection
To prepare an injection solution:
40 mg Injection
For a reconstituted solution of 8 mg/ml of esomeprazole: Prepare the solution by adding 5 ml of sodium chloride 0.9% for intravenous use to the vial of esomeprazole 40 mg.
The reconstituted solution for injection must be administered intravenously over a period of at least 3 minutes.
For more information on dose administration, please see the summary of product characteristics, section 4.2.
Nexium Infusion
To prepare an infusion solution:
40 mg Infusion
Dissolve the contents of one vial of esomeprazole 40 mg in up to 100 ml of sodium chloride 0.9% for intravenous use.
80 mg Infusion
Dissolve the contents of two vials of esomeprazole 40 mg in up to 100 ml of sodium chloride 0.9% for intravenous use.
For more information on dose administration, please consult the summary of product characteristics, section 4.2.
Disposal
Any remaining medication or waste material must be disposed of in accordance with local procedures.